Summary:
Phase 3 randomized, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 Cytomegalovirus (CMV) vaccine in healthy female participants 18-40 years of age
Qualified Participants Must:
• Be a biological female
• Be between ages 18-40
• Be in stable health
• Have direct exposure to a child 5 years or younger at least 8 hours per week
• Must be able to attend 13 clinic visits over 30 months at our Lenexa, Kansas location
Qualified Participants May Receive:
Compensation up to $3,515